MG
NKTR icon

MilWealth Group’s Nektar Therapeutics NKTR Stock Holding History

MilWealth Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7
Closed -$317 – 61
2022
Q3 		$317 Hold
7
– – ﹤0.01% 59
2022
Q2 		$377 Hold
7
– – ﹤0.01% 69
2022
Q1 		$534 Hold
7
– – ﹤0.01% 76
2021
Q4 		$1.34K Hold
7
– – ﹤0.01% 144
2021
Q3 		$1.78K Hold
7
– – ﹤0.01% 145
2021
Q2 		$1.7K Hold
7
– – ﹤0.01% 56
2021
Q1 		$1.98K Hold
7
– – ﹤0.01% 58
2020
Q4 		$1.68K Hold
7
– – ﹤0.01% 52
2020
Q3 		$1.64K Hold
7
– – ﹤0.01% 53
2020
Q2 		$2.29K Hold
7
– – ﹤0.01% 57
2020
Q1 		$1.77K Hold
7
– – ﹤0.01% 62
2019
Q4 		$2.14K Hold
7
– – ﹤0.01% 65
2019
Q3 		$1.8K Buy
+7
New +$2.57K ﹤0.01% 65

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

MilWealth Group's NKTR Position: Q4 2022 in Review

MilWealth Group sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 7 shares — an estimated $317 sold.

MilWealth Group first reported a position in NKTR in Q3 2019 and held it in 13 quarters. The position peaked at $2.29K in Q2 2020. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.

  • MilWealth Group reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
  • MilWealth Group sold 7 Nektar Therapeutics shares in Q4 2022, an estimated $317.
  • MilWealth Group first reported a position in Nektar Therapeutics in Q3 2019 and held it in 13 quarters.
  • MilWealth Group's Nektar Therapeutics position peaked at $2.29K in Q2 2020.
  • 214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.

Based on MilWealth Group's 13F filing for Q4 2022, filed 9 May 2023.